The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
Thirty pagetic patients were treated for 6 months with a daily nasal application of 2 mg of synthetic human calcitonin (hCT). Serum alkaline phosphatases (SAP) and urinary hydroxyproline/creatinine ratio (OH/Cr), reflecting bone turnover, were significantly reduced from the first month of treatment (mean +/- SEM: SAP, -13.9 +/- 2.2%; OH/Cr, -22.2 +/- 5.8%; both P less than 0.01) and until the end of the 6-month course (mean +/- SEM: SAP, -29.7 +/- 4.6%; OH/Cr, -22.5 +/- 5.9%; both P less than 0.01). Nasal hCT was perfectly tolerated both locally and systemically. These results allow us to consider nasal hCT for long-term trials in metabolic bone diseases characterized by a relative increase of bone resorption.
Reginster
J Y
JY
Department of Rheumatology and Endocrinology, University of Liège, Belgium.
Jeugmans-Huynen
A M
AM
Wouters
M
M
Sarlet
N
N
McIntyre
H D
HD
Franchimont
P
P
D000281:Administration, Intranasal; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D002116:Calcitonin / Q000008:administration & dosage* / Q000627:therapeutic use; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism
D002116:Calcitonin; D003404:Creatinine; D000469:Alkaline Phosphatase; D006909:Hydroxyproline